LiverLearning®: Chronic Liver Failure SIG & Portal Hypertension SIG: Acute and Chronic Kidney Failure in Cirrhosis: Mechanisms to Management

This two-session program explores the pathophysiology, diagnosis and treatment of kidney failure in patients with cirrhosis. The first session reviews chronic kidney manifestations of portal hypertension, including sodium retention, ascites and chronic kidney failure. The second session discusses acute kidney injury in ACLF. Each part includes a case presentation to highlight management controversies, expert panel interviews and Q&A.

LiverLearning®: Hepatitis B SIG: Updates and Controversies in HBV: Management, HCC Surveillance and Emerging Therapies

This two-hour symposium explores chronic hepatitis B management in diverse populations. Topics include the changing global epidemiology and comorbidity of chronic hepatitis B, how to apply current practice guidelines in “gray” zones, HCC prevention strategies beyond the guidelines, emerging curative therapies and current strategies in HCC surveillance for hepatitis B, especially in younger, noncirrhotic persons from endemic areas.

Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model

Berangere Gapp, Marie Jourdain, Pauline Bringer, Benjamin Kueng, Delphine Weber, Arnaud Osmont, Stefan Zurbruegg, Judith Knehr, Rocco Falchetto, Guglielmo Roma, William Dietrich, Reginald Valdez, Nicolau Beckmann, Florian Nigsch, Arun J. Sanyal, Iwona Ksiazek – 8 November 2019 – A promising approach for the treatment of nonalcoholic steatohepatitis (NASH) is the inhibition of enhanced hepatic de novo lipogenesis (DNL), which is the synthesis of fatty acids from nonlipid sources.

Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints

Naim Alkhouri, Rohit Kohli, Ariel E. Feldstein – 8 November 2019 – Nonalcoholic fatty liver disease (NAFLD) is common in children and may progress to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and even cirrhosis in childhood or early adulthood, indicating the need for pharmacologic treatment in this age group. Multiple trials are evaluating different therapeutic targets for NASH with fibrosis in adults, and the U.S.

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach

Guohong Han, Sarah Berhane, Hidenori Toyoda, Dominik Bettinger, Omar Elshaarawy, Anthony W. H. Chan, Martha Kirstein, Cristina Mosconi, Florian Hucke, Daniel Palmer, David J. Pinato, Rohini Sharma, Diego Ottaviani, Jeong W. Jang, Tim A. Labeur, Otto M. Delden, Mario Pirisi, Nick Stern, Bruno Sangro, Tim Meyer, Waleed Fateen, Marta García‐Fiñana, Asmaa Gomaa, Imam Waked, Eman Rewisha, Guru P. Aithal, Simon Travis, Masatoshi Kudo, Alessandro Cucchetti, Markus Peck‐Radosavljevic, R.B. Takkenberg, Stephen L. Chan, Arndt Vogel, Philip J. Johnson – 7 November 2019

Stathmin 1 Induces Murine Hepatocyte Proliferation and Increased Liver Mass

Enpeng Zhao, Yang Shen, Muhammad Amir, Alton B. Farris, Mark J. Czaja – 7 November 2019 – The endogenous cellular signals that initiate the transition of hepatocytes from quiescence to proliferation remain unclear. The protein stathmin 1 (STMN1) is highly expressed in dividing cells, including hepatocytes, and functions to promote cell mitosis through physical interactions with tubulin and microtubules that regulate mitotic spindle formation.

Pregenomic HBV RNA and Hepatitis B Core‐Related Antigen Predict Outcomes in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy

Ivana Carey, Jeffrey Gersch, Bo Wang, Christiana Moigboi, Mary Kuhns, Gavin Cloherty, Geoffrey Dusheiko, Kosh Agarwal – 7 November 2019

Subscribe to